SG11201404249RA - Transmucosal administration system for a pharmaceutical drug - Google Patents
Transmucosal administration system for a pharmaceutical drugInfo
- Publication number
- SG11201404249RA SG11201404249RA SG11201404249RA SG11201404249RA SG11201404249RA SG 11201404249R A SG11201404249R A SG 11201404249RA SG 11201404249R A SG11201404249R A SG 11201404249RA SG 11201404249R A SG11201404249R A SG 11201404249RA SG 11201404249R A SG11201404249R A SG 11201404249RA
- Authority
- SG
- Singapore
- Prior art keywords
- administration system
- transmucosal administration
- pharmaceutical drug
- drug
- pharmaceutical
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/354,714 US10806703B2 (en) | 2012-01-20 | 2012-01-20 | Transmucosal administration system for a pharmaceutical drug |
| PCT/EP2013/050822 WO2013107810A1 (en) | 2012-01-20 | 2013-01-17 | Transmucosal administration system for a pharmaceutical drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201404249RA true SG11201404249RA (en) | 2014-08-28 |
Family
ID=47559517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201404249RA SG11201404249RA (en) | 2012-01-20 | 2013-01-17 | Transmucosal administration system for a pharmaceutical drug |
Country Status (17)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9750705B2 (en) | 2012-08-31 | 2017-09-05 | The Regents Of The University Of California | Agents useful for treating obesity, diabetes and related disorders |
| KR20150138671A (ko) * | 2014-06-02 | 2015-12-10 | 에스케이케미칼주식회사 | 타달라필을 함유하는 구강 붕해 필름 및 이의 제조방법 |
| US20160243036A1 (en) * | 2015-02-25 | 2016-08-25 | Intelgenx Corp. | Film dosage forms containing amorphous active agents |
| CA3008849A1 (en) | 2015-12-17 | 2017-06-22 | Bioelectron Technology Corporation | Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| DE102017104277A1 (de) | 2017-03-01 | 2018-09-06 | Lts Lohmann Therapie-Systeme Ag | Transmukosales Verabreichungssystem für Idebenon |
| US12310967B2 (en) | 2017-12-21 | 2025-05-27 | Gliapharm Sa | Compositions and methods of treatment for neurological disorders comprising motor neuron diseases |
| US12274703B2 (en) | 2017-12-21 | 2025-04-15 | Gliapharm Sa | Compositions and methods of treatment for neurological disorders comprising a dementia |
| JP7365409B2 (ja) | 2018-06-28 | 2023-10-19 | エイアールエックス エルエルシー | 溶解性単位用量膜構造物を製造するための分配方法 |
| US10828254B2 (en) | 2018-09-28 | 2020-11-10 | Intelgenx Corp. | Oral film formulation for modulating absorption profile |
| US12303501B2 (en) | 2018-11-05 | 2025-05-20 | Intelgenx Corp. | Lipophilic active oral film formulation and method of making the same |
| WO2020132378A2 (en) | 2018-12-22 | 2020-06-25 | Gliapharm Sa | Compositions and methods of treatment for neurological disorders comprising depression |
| WO2022258629A1 (en) | 2021-06-07 | 2022-12-15 | Katholieke Universiteit Leuven | Idebenone in the treatment of drug resistant epilepsy |
| US12440472B2 (en) | 2021-06-16 | 2025-10-14 | Intelgenx Corp. | Stable tryptamine oral films |
| AU2022306868A1 (en) | 2021-07-08 | 2024-02-22 | Ptc Therapeutics, Inc. | Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione |
| CN113827585B (zh) * | 2021-10-27 | 2023-04-11 | 山东大学齐鲁医院 | 艾地苯在治疗肢带型肌营养不良2g型中的应用 |
| AU2023322319A1 (en) * | 2022-08-10 | 2025-02-20 | Intelgenx Corp. | High loading oral film formulation with improved bioavailability |
| CN116172993A (zh) * | 2023-04-27 | 2023-05-30 | 潍坊医学院附属医院 | 艾地苯醌在制备预防和/或治疗脑缺血再灌注损伤的药物中的应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07103018B2 (ja) * | 1988-09-16 | 1995-11-08 | 武田薬品工業株式会社 | 精神分裂病治療剤 |
| ES2062634T3 (es) * | 1990-08-30 | 1994-12-16 | Senju Pharma Co | Composicion con liberacion controlada del farmaco. |
| JP3469926B2 (ja) * | 1993-11-04 | 2003-11-25 | 太田製薬株式会社 | 大腸内放出型医薬製剤用粒状物 |
| JPH08291063A (ja) * | 1995-04-21 | 1996-11-05 | Maruho Kk | 易吸収性製剤及びその製造法 |
| JPH1053520A (ja) * | 1996-06-03 | 1998-02-24 | Takeda Chem Ind Ltd | 抗疲労剤 |
| US5800832A (en) | 1996-10-18 | 1998-09-01 | Virotex Corporation | Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces |
| DE19646392A1 (de) | 1996-11-11 | 1998-05-14 | Lohmann Therapie Syst Lts | Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht |
| DE19652268C2 (de) | 1996-12-16 | 2000-06-29 | Lohmann Therapie Syst Lts | Arzneizubereitung für die Freisetzung von Apomorphin in der Mundhöhle |
| DE19802050A1 (de) * | 1998-01-21 | 1999-07-22 | Labtec Gmbh | Zubereitung zur Freisetzung von Coenzym Q 10 in die Mundhöhle |
| US6264981B1 (en) * | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
| JP2004522802A (ja) * | 2001-02-16 | 2004-07-29 | ラヴィファーム・ラボラトリーズ・インク | 水溶性で風味良い複合体 |
| ATE253353T1 (de) * | 2001-04-12 | 2003-11-15 | Vesifact Ag | Coenzym q10 enthaltende mikroemulsion- prekonzentrate und mikroemulsionen |
| FR2832311B1 (fr) * | 2001-11-21 | 2004-04-16 | Besins Int Belgique | Poudre filmogene, compositions la comprenant, leurs procedes de preparation et leurs utilisations |
| JP2004043450A (ja) | 2002-05-16 | 2004-02-12 | Kyukyu Yakuhin Kogyo Kk | 速溶性フィルム状製剤 |
| CN1520805A (zh) * | 2003-01-30 | 2004-08-18 | 日清药业股份有限公司 | 含有泛醌的组合物 |
| DE10328942A1 (de) | 2003-06-27 | 2005-01-27 | Lts Lohmann Therapie-Systeme Ag | Transmukosale Darreichungsformen mit verminderter Schleimhautirritation |
| KR100974202B1 (ko) | 2003-08-22 | 2010-08-06 | 안티포딘 파마슈티칼스, 인코포레이티드 | 미토콘드리아 표적화 산화방지제로서 사용되는 미토퀴논 유도체, 이의 제조방법 및 이를 포함하는 약제학적 조성물 |
| DE102005015128B4 (de) * | 2005-03-31 | 2008-12-11 | Bayer Schering Pharma Aktiengesellschaft | Wafer enthaltend Steroidhormone |
| EP1891946A1 (en) * | 2006-08-14 | 2008-02-27 | Santhera Pharmaceuticals (Schweiz) AG | Transmucosal administration of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone |
| EP2108366B1 (en) | 2008-04-09 | 2011-10-19 | Santhera Pharmaceuticals (Schweiz) AG | Idebenone for the treatment of respiratory illness in muscular dystrophy |
| JP2011207847A (ja) * | 2010-03-30 | 2011-10-20 | Nitto Denko Corp | フィルム状製剤及びその製造方法 |
-
2012
- 2012-01-20 US US13/354,714 patent/US10806703B2/en active Active
-
2013
- 2013-01-17 ES ES13700330T patent/ES2725567T3/es active Active
- 2013-01-17 SG SG11201404249RA patent/SG11201404249RA/en unknown
- 2013-01-17 US US14/372,878 patent/US10716762B2/en active Active
- 2013-01-17 CA CA2861925A patent/CA2861925A1/en not_active Abandoned
- 2013-01-17 KR KR1020147023042A patent/KR20140113733A/ko not_active Ceased
- 2013-01-17 MX MX2014008782A patent/MX2014008782A/es unknown
- 2013-01-17 CN CN201380005891.3A patent/CN104271123B/zh not_active Expired - Fee Related
- 2013-01-17 JP JP2014552620A patent/JP2015504078A/ja active Pending
- 2013-01-17 AU AU2013211078A patent/AU2013211078B2/en not_active Ceased
- 2013-01-17 WO PCT/EP2013/050822 patent/WO2013107810A1/en active Application Filing
- 2013-01-17 ES ES18212173T patent/ES2835178T3/es active Active
- 2013-01-17 EP EP18212173.1A patent/EP3488846B1/en active Active
- 2013-01-17 NZ NZ627171A patent/NZ627171A/en not_active IP Right Cessation
- 2013-01-17 BR BR112014017756A patent/BR112014017756A8/pt not_active IP Right Cessation
- 2013-01-17 EP EP13700330.7A patent/EP2804596B8/en active Active
- 2013-01-17 RU RU2014133953A patent/RU2639369C2/ru not_active IP Right Cessation
- 2013-01-17 HK HK15101372.9A patent/HK1200734A1/xx unknown
-
2014
- 2014-07-09 ZA ZA2014/05022A patent/ZA201405022B/en unknown
- 2014-07-17 IL IL233693A patent/IL233693A/en not_active IP Right Cessation
-
2017
- 2017-06-27 JP JP2017124923A patent/JP2017206531A/ja active Pending
-
2019
- 2019-02-15 JP JP2019024977A patent/JP7285650B2/ja active Active
- 2019-08-05 US US16/531,707 patent/US20190350872A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL233693A0 (en) | A system for transmucosal administration of a medicinal preparation | |
| ZA201502352B (en) | Liposomal drug delivery system | |
| IL238903A0 (en) | Case for drug release devices | |
| HUE061532T2 (hu) | Gyógyszerbejuttató eszköz | |
| AU2013344654A1 (en) | Oral transmucosal drug delivery system | |
| EP2921152A4 (en) | DRUG DELIVERY SYSTEM | |
| ZA201309156B (en) | Drug delivery system | |
| EP2842539A4 (en) | DRUG DELIVERY SYSTEM | |
| ZA201405797B (en) | Pharmaceutical dosage form | |
| AP2015008208A0 (en) | Pharmaceutical administration forms comprising | |
| SG10202102293QA (en) | A novel drug delivery system based on jcv-vlp | |
| ZA201406206B (en) | A drug delivery system | |
| EP2841128A4 (en) | PISTON CLOSURES FOR MEDICINAL PACKAGING CAPSULES | |
| IL234912A0 (en) | Drug release device | |
| GB201211535D0 (en) | Drug delivery device for simultaneously delivering at least two medicaments | |
| IL236354A0 (en) | Arrangement for drug delivery device | |
| GB201211538D0 (en) | Drug delivery device for simultaneously delivering at least two medicaments | |
| IL227651A0 (en) | Pharmaceutical formulations for local introduction containing 220b | |
| ZA201306823B (en) | Excipient system for topical delivery of pharmaceutical agents | |
| EP2768488A4 (en) | TWO-PHASE PHARMACEUTICAL DELIVERY SYSTEM | |
| ZA201502354B (en) | Pharmaceutical dosage form | |
| HUE049542T2 (hu) | Gyógyszerbejuttató eszköz | |
| HUE049546T2 (hu) | Gyógyszerbejuttató eszköz | |
| GB201218668D0 (en) | Drug delivery device |